Dimensional Fund Advisors LP Has $12.96 Million Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Dimensional Fund Advisors LP cut its position in REGENXBIO Inc. (NASDAQ:RGNX) by 7.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,107,453 shares of the biotechnology company’s stock after selling 89,620 shares during the period. Dimensional Fund Advisors LP owned 2.25% of REGENXBIO worth $12,957,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. grew its holdings in REGENXBIO by 73.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 746 shares during the last quarter. ProShare Advisors LLC boosted its position in REGENXBIO by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 874 shares during the last quarter. Maryland State Retirement & Pension System increased its stake in shares of REGENXBIO by 7.2% in the 2nd quarter. Maryland State Retirement & Pension System now owns 15,800 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 1,067 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of REGENXBIO by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 18,177 shares of the biotechnology company’s stock worth $383,000 after acquiring an additional 1,438 shares during the last quarter. Finally, Arizona State Retirement System lifted its stake in shares of REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 1,997 shares during the period. 88.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on RGNX shares. HC Wainwright reiterated a “buy” rating and set a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, Barclays dropped their price objective on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.91.

REGENXBIO Stock Up 4.0 %

REGENXBIO stock opened at $9.72 on Friday. The company has a fifty day simple moving average of $11.94 and a 200 day simple moving average of $14.16. REGENXBIO Inc. has a 1-year low of $9.29 and a 1-year high of $28.80.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The company had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $22.97 million. During the same period in the prior year, the firm earned ($1.66) EPS. REGENXBIO’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, equities analysts expect that REGENXBIO Inc. will post -4.66 earnings per share for the current fiscal year.

Insider Transactions at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other REGENXBIO news, Director Kenneth T. Mills sold 12,221 shares of the company’s stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $13.78, for a total transaction of $168,405.38. Following the completion of the sale, the director now directly owns 408,035 shares in the company, valued at $5,622,722.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Argeris N. Karabelas sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,279 shares of company stock worth $864,034. 13.13% of the stock is owned by insiders.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.